# A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

> **NCT02132949** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 401 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** 5-Fluorouracil
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Doxorubicin
- **DRUG:** Epirubicin
- **DRUG:** Paclitaxel
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02132949
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-14
- **Primary completion:** 2016-03-03
- **Final completion:** 2020-08-25
- **Target enrollment:** 401 (ACTUAL)
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132949, "A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02132949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*